Clinical trial
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV…
NCT00445848 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00445848 |
|---|---|
| Title | S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, erlotinib hydrochloride |
| Enrollment | 89 |
| Start date | Jul 1, 2007 |
| Primary completion | Aug 1, 2013 |
| Completion | Jan 1, 2014 |
| First posted | Mar 9, 2007 |
| Last update posted | Mar 5, 2020 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: